Comparing Neuronetics (STIM) and Its Competitors

Neuronetics (NASDAQ: STIM) is one of 121 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its rivals? We will compare Neuronetics to related companies based on the strength of its profitability, dividends, institutional ownership, analyst recommendations, risk, valuation and earnings.

Analyst Ratings

This is a summary of recent recommendations and price targets for Neuronetics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuronetics 0 0 5 0 3.00
Neuronetics Competitors 814 2815 4988 252 2.53

Neuronetics currently has a consensus target price of $32.25, indicating a potential upside of 107.26%. As a group, “Surgical & medical instruments” companies have a potential upside of 28.81%. Given Neuronetics’ stronger consensus rating and higher probable upside, research analysts clearly believe Neuronetics is more favorable than its rivals.

Profitability

This table compares Neuronetics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuronetics N/A N/A N/A
Neuronetics Competitors -30.00% -41.48% -13.59%

Institutional & Insider Ownership

68.7% of Neuronetics shares are owned by institutional investors. Comparatively, 50.8% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 12.0% of Neuronetics shares are owned by insiders. Comparatively, 15.9% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Neuronetics and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Neuronetics $52.78 million -$24.10 million -5.78
Neuronetics Competitors $1.48 billion $146.48 million 39.08

Neuronetics’ rivals have higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Neuronetics beats its rivals on 7 of the 12 factors compared.

About Neuronetics

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.